News - Events

Antimicrobial resistance (AMR) describes the ability of a microorganism like bacteria, viruses and some parasites to stop an antibiotic, antiviral drug or antimalarial drug from working. As a result, standard treatments for many serious diseases become ineffective, the infections persist and an increasing number of people are harmed. A subset of AMR is antibacterial resistance.

This meeting will look at different aspects of developing and delivering pre-filled syringes such as on-body injectors and container closure interaction. Delegates will learn about the changing global marketplace and challenges facing the industry.

BioTrinity is a long-running two-day life sciences conference that will take place in 2020 in central London from 28-29 April. The conference focuses on partnering, investment and collaboration, and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.

This meeting will review the current state of pain treatment including issues around opioid-based treatments. Discussions will focus on drug development from the preclinical to clinical stage and candidate treatments in the pipelines of leading pharmaceutical companies. There will also be a review of non-opioid targets for pain medications including the cannabinoid receptor 2 and other targets. The therapeutic efficacy of neurotoxins will also be addressed, including novel botulinum-based constructs.

This year’s meeting will focus on advances in drug product formulation and innovations in device design and development to aid delivery. It will also include a discussion of new therapeutic applications such as the delivery of siRNA.

The Advanced Therapies Congress brings the life science community together to discuss the challenges of bringing ATMPs to market. The event covers each stage in the development of cell, gene and immunotherapy – from bioprocessing through clinical development to reimbursement and delivery to patients.

This third annual event will look at the insights that can be generated by the use of real-world data to evaluate the effectiveness of pharmaceuticals, and how this data can help industry, payers and healthcare professionals take decisions.  

The pharmaceutical microbiology industry has seen many changes in recent years. These changes include the discovery of new methods for multiplying microbial organisms, enhanced knowledge of the human microbiome, and new regulation. This meeting will bring together experts from industry to discuss data integrity as it affects microbiology methods, environmental monitoring and automated endotoxin testing and process automation.